Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Regulus Therapeutics Inc (NASDAQ: RGLS) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Regulus Therapeutics Inc (NASDAQ: RGLS) concerning whether a series of statements by Regulus Therapeutics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On June 27, 2016, Regulus revealed that it had received verbal notice from the U.S. Food and Drug Administration ("FDA") regarding the Company's new drug for the treatment of chronic hepatitis C virus infection which was under review by the FDA, has now been placed on clinical hold after a second serious case of jaundice was reported.  

On this news, shares of Regulus were down more than 47% on intraday trading on June 28, 2016.

Based in San Diego, CA, and founded in 2007 Regulus Therapeutics Inc focuses on the discovery and development of drugs that target RNAs to treat a range of diseases.

If you purchased shares of Regulus Therapeutics Inc (NASDAQ: RGLS) on or before On June 27, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185